Brentuximab Vedotin (Genetical Recombination)(Seagen / Takeda)은 Peripheral T Cell Lymphoma 표적 ADC로, Untreated CD30-Positive Hodgkin's Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen. 전임상 단계입니다. 대표 임상 효능: ORR 89.5% (ClinicalTrials.gov NCT02588651). 차별점: Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic.
Peripheral T Cell Lymphoma
Untreated CD30-Positive Hodgkin's Lymphoma
Active
ADCs) increased the antitumor effect of mAbs
vedotin and the anti-HER2 trastuzumab deruxteca
linker, or payload that have limited their development
humanized antibodies and, subsequently, fully human antibodies for cancer therapy, thereby avoiding the side
Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic
targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen
macrophages, indicating immune activation
payload that have limited their development
biomarkers for HBsAg clearance and responses to Peg-IFN-α in HBeAg-negative chronic hepatitis B patient
resistance mechanisms and improving outcomes in relapsed or refractory disease
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Brentuximab Vedotin (Genetical Recombination)(Seagen / Takeda)은 Peripheral T Cell Lymphoma 표적 ADC로, Untreated CD30-Positive Hodgkin's Lymphoma 영역에서 개발·상용화 중입니다. 작용기전: targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen. 전임상 단계입니다. 대표 임상 효능: ORR 89.5% (ClinicalTrials.gov NCT02588651). 차별점: Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic.
Peripheral T Cell Lymphoma
Untreated CD30-Positive Hodgkin's Lymphoma
Active
ADCs) increased the antitumor effect of mAbs
vedotin and the anti-HER2 trastuzumab deruxteca
linker, or payload that have limited their development
humanized antibodies and, subsequently, fully human antibodies for cancer therapy, thereby avoiding the side
Novel-Agent-Based Front-Line Therapy in Older Adults Aged ≥ 60 Years With Classic Hodgkin Lymphoma: A Systematic
targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen
macrophages, indicating immune activation
payload that have limited their development
biomarkers for HBsAg clearance and responses to Peg-IFN-α in HBeAg-negative chronic hepatitis B patient
resistance mechanisms and improving outcomes in relapsed or refractory disease
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.